ADRX-0706 expansion-cohort results
Adcentrx reported initial dose-escalation data for its Nectin-4 ADC ADRX-0706 in 2025. Expansion-cohort results would provide different clinical evidence from that earlier presentation.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Pin tumor type, analysis set and timepoint; a cross-tumor response anecdote does not satisfy a designated cohort endpoint.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Expansion readout candidate — date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links adcentrx.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof.
Potential outcome market
Will Adcentrx publicly report the designated ADRX-0706 Phase 1b expansion-cohort analysis by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.